Buddleja officinalis polysaccharide as well as preparation method and application thereof
The polysaccharide BOM0.05S2 extracted and purified from Mimenghua solved the problem of lack of safe treatment drugs for liver fibrosis. By reducing liver damage indicators and collagen fiber deposition, the intestinal mucophilin Akmania is enriched, and the intestinal mucophilin is achieved. Potential therapeutic effects on liver fibrosis.
Patent Information
- Application Number
- CN202411340596.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-24
- Publication Date
- 2024-11-19
Smart Images

Figure BDA0005059578050000081 
Figure BDA0005059578050000091 
Figure HDA0005059578220000011
Abstract
Description
Technical Field
[0001] The invention belongs to the field of polysaccharides, and in particular relates to a polysaccharide extracted from Buddleja officinalis. Maxim., as well as a preparation method and application of the polysaccharide. Background Art
[0002] Liver fibrosis is a common pathological process of many chronic liver diseases. According to conservative statistics, 1.5 billion people suffer from chronic liver disease worldwide, making liver fibrosis a global burden. When liver tissue is repeatedly or continuously damaged, scar reaction will occur in the liver parenchyma, forming liver fibrosis. Studies have shown that timely intervention in the process of liver fibrosis seems to be reversible. Although great progress has been made in the understanding of the cellular and molecular mechanisms of liver fibrosis, there is currently no safe and effective drug for the treatment of liver fibrosis. Therefore, there is an urgent need to screen out safe and non-toxic substances to exert their potential effectiveness in treating or preventing liver fibrosis.
[0003] Buddleja officinalis Maxim. is a shrub of the genus Buddleja in the family Loganaceae. It has a long history of application in China as a traditional Chinese medicine and tea. In addition, its high pigment content also makes it commonly used as a natural dye for textiles and a food coloring in cooking. Buddleja officinalis Maxim. is slightly cold in nature, sweet in taste, and belongs to the liver meridian. It is used for red and swollen eyes, excessive tears and photophobia, eye cataracts, liver deficiency and dark eyes, and blurred vision. Buddleja officinalis was first recorded in the "Kaibao Materia Medica" and has the effects of clearing heat and purging fire, nourishing the liver and improving eyesight, and removing cataracts. It is reported that the main components of Buddleja officinalis include polysaccharides, flavonoids, phenylethanol glycosides and terpenoids. Summary of the invention
[0004] The present invention uses a simple and effective process and method for extracting and purifying plant polysaccharides, obtains a mixed polysaccharide component using Buddleja buddleja as a raw material, and further purifies to obtain a uniform polysaccharide BOM0.05S2. Pharmacological experiments show that polysaccharide BOM0.05S2 can significantly reduce serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), laminin (LN), hyaluronidase (HA), type III procollagen (PC-III), type IV collagen (IV-C) and other indicators in the liver; in addition, polysaccharide BOM0.05S2 can significantly reduce the deposition of collagen fibers in the liver and the expression of α-SMA protein in liver tissue; further, it is found that polysaccharide BOM0.05S2 can enrich intestinal muciniphila Akkermansia (Akkermansia muciniphila).
[0005] Based on this, the object of the present invention is to provide a Buddleja polysaccharide BOM0.05S2, a preparation method thereof and its use in the preparation of drugs for preventing and / or treating liver fibrosis and diseases associated with intestinal Akkermansia muciniphila.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] In the first aspect, the present invention provides a Buddleja buddleja polysaccharide BOM0.05S2, whose monosaccharide composition includes 40-50% galactose, 20-40% arabinose, 1-10% glucose, 1-10% mannose, 1-10% rhamnose, 1-10% galacturonic acid and 1-10% glucuronic acid, based on the total molar amount of all monosaccharides contained in the polysaccharide as 100%.
[0008] Further preferably, the monosaccharide composition of the Buddleja buddleja polysaccharide BOM0.05S2 includes galactose, arabinose, glucose, mannose, rhamnose, galacturonic acid and glucuronic acid. Based on the total molar amount of all monosaccharides contained in the polysaccharide as 100%, the proportions are 47.94%, 29.12%, 7.85%, 7.64%, 3.61%, 2.20% and 1.64%, respectively.
[0009] Specifically, the structure of the Buddleja buddleja polysaccharide BOM0.05S2 includes 1 main chain and 4 side chains, wherein:
[0010] The main chain is mainly composed of 1,4-α-GalA, 1,2,4-α-Rha, 1,4-α-GlcA, 1,4-α-Glc, 1,4,6-α-Glc, 1,4-β-Man and terminal-β-Gal;
[0011] The four branches and their connection with the main chain are as follows:
[0012] Branch 1: composed of 1,4-β-Gal and T-α-Ara, and connected to C-4 of the main chain 1,2,4-α-Rha by 1,4-β-Gal;
[0013] Branch 2: It is composed of T-α-Ara, 1,5-α-Ara and 1,3,5-α-Ara, and 1,5-α-Ara is connected to C-4 of the main chain 1,2,4-α-Rha;
[0014] Branch 3: composed of alternately connected 1,3,6-β-Gal and 1,6-β-Gal, T-α-Ara and T-β-Man further connect C-3 of 1,3,6-β-Gal in branch 3, and branch 3 is connected to C-4 of main chain 1,2,4-α-Rha by 1,3,6-β-Gal;
[0015] Branch 4: consists of T-α-Glc, attached to C-6 of the main chain 1,4,6-α-Glc.
[0016] Furthermore, the molecular weight of the Buddleja buddleja polysaccharide BOM0.05S2 is in the range of 3 to 30 kDa, preferably 10 to 20 kDa, and more preferably 13.6 kDa.
[0017] In a second aspect, the present invention provides a method for preparing the Buddleja buddleja polysaccharide BOM0.05S2 described in the first aspect, comprising the following steps:
[0018] (1) Polysaccharide extraction: extract the Buddleja buddha flower with boiling water to obtain an extract; concentrate the extract, add ethanol aqueous solution to the obtained concentrate for alcohol precipitation, let it stand, separate the precipitate, and dry it to obtain crude Buddleja buddha flower polysaccharide BOM;
[0019] (2) Polysaccharide purification:
[0020] (i) dissolving the crude polysaccharide BOM of Buddleja buddleja obtained in step (1) in water and centrifuging, taking the supernatant, and performing preliminary purification using an anion exchange column, eluting with water and 0.05 M NaCl aqueous solution in sequence, collecting the eluted fraction of 0.05 M NaCl aqueous solution, and obtaining the polysaccharide fraction BOM0.05 of Buddleja bud ...
[0021] (ii) dissolving the Buddleja buddleja polysaccharide component BOM0.05 obtained in step (i) in water and centrifuging the solution, taking the supernatant and purifying it through a gel column to obtain the Buddleja buddleja polysaccharide BOM0.05S2.
[0022] Preferably, in step (1), before boiling water extraction, the Buddleja buddleja is first soaked in an ethanol aqueous solution (e.g., an ethanol aqueous solution with a volume fraction of 80 to 98%, such as 95%) for 3 to 10 days (e.g., 7 days), and then dried (e.g., air-dried).
[0023] Preferably, in step (1), in the boiling water extraction, the weight of Buddleja buddleja / water volume ratio is 1: 10 to 20, preferably 1: 12 to 14, unit: kg / L; the number of boiling water extraction is 3 to 10 times, preferably 8 times, each time for 3 to 5 hours, preferably 4 hours.
[0024] Preferably, in step (1), the extract is concentrated to 1 / 40 to 1 / 25 of its volume before concentration, preferably 1 / 40.
[0025] Preferably, in step (1), the volume fraction of the ethanol aqueous solution is 80-98%, preferably 95%; the volume of the ethanol aqueous solution used for alcohol precipitation is 3-6 times, for example 4 times, that of the concentrated solution.
[0026] Preferably, in step (1), before the concentrate is subjected to alcohol precipitation, the concentrate is first centrifuged, and then the supernatant of the centrifugation is dialyzed in water for 24 to 72 hours; thereafter, the dialyzed liquid is added to the ethanol aqueous solution for alcohol precipitation.
[0027] Preferably, in step (1), the standing time is 6 to 24 hours, for example 12 hours.
[0028] Preferably, the crude polysaccharide BOM of Buddleja buddleja obtained in step (1) is washed and then dried before the polysaccharide purification in step (2), and can be washed alternately with ethanol and acetone, each washing for 2 to 4 times.
[0029] Preferably, in step (i), during the dissolution process, the weight ratio of Buddleja buddleja crude polysaccharide BOM to the volume ratio of water is 1:2 to 20, such as 1:10, unit: g / mL.
[0030] Preferably, in step (i), the anion exchange column is selected from the following models: DEAE Sepharose TM FastFlow, DEAE cellucose-52, preferably DEAE Sepharose TM Fast Flow.
[0031] Preferably, step (i) further comprises concentrating the eluted fraction of the collected 0.05M NaCl aqueous solution, dialyzing it in water, and drying it to obtain the Buddleja buddleja polysaccharide component BOM0.05.
[0032] Preferably, in step (ii), during the dissolution process, the ratio of crude buddleja ...
[0033] Preferably, in step (ii), the gel column is selected from the following models: Sephacryl S-200HR, Sephacryl S-300HR, Sephadex G-100 and Sephadex G-150, preferably Sephacryl S-200HR.
[0034] Preferably, in step (ii), the eluent used for purifying the supernatant by gel column is 0.2 M NaCl aqueous solution.
[0035] Preferably, step (ii) further comprises collecting the eluted fractions and drying (eg freeze-drying) them to obtain Buddleja buddleja polysaccharide BOM0.05S2.
[0036] In a third aspect, the present invention provides a pharmaceutical composition comprising the Buddleja buddleja polysaccharide BOM0.05S2 described in the first aspect or the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method described in the second aspect, and pharmaceutically acceptable excipients.
[0037] In a fourth aspect, the present invention provides the use of the Buddleja buddleja polysaccharide BOM0.05S2 described in the first aspect, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of drugs, reagents, diets or nutritional supplements having one or more of the following effects:
[0038] a. Improve serum aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) levels;
[0039] b. Reduction of laminin (LN), hyaluronidase (HA), type III procollagen (PC-III) and / or type IV collagen (IV-C) in the liver;
[0040] c. Inhibit the deposition of collagen fibers in liver tissue;
[0041] d. Enrichment of intestinal Akkermansia muciniphila.
[0042] Among them, in use a, improvement refers to reducing the level of aspartate aminotransferase (AST) and / or alanine aminotransferase (ALT) caused by liver damage; further, liver damage can be caused by chronic liver fibrosis.
[0043] In the fifth aspect, the present invention provides the use of the Buddleja buddleja polysaccharide BOM0.05S2 described in the first aspect, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of drugs for preventing and / or treating liver fibrosis and / or liver damage.
[0044] In a specific embodiment, the liver fibrosis is associated with Akkermansia muciniphila in the intestine.
[0045] In the sixth aspect, the present invention provides the use of the Buddleja buddleja polysaccharide BOM0.05S2 described in the first aspect, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of drugs for treating diseases related to intestinal Akkermansia muciniphila.
[0046] The diseases associated with Akkermansia muciniphila include, but are not limited to, inflammatory bowel disease, obesity, diabetes, fatty liver, liver fibrosis, and the like.
[0047] Beneficial effects:
[0048] The Buddleja buddleja polysaccharide BOM0.05S2 extracted and purified from Buddleja buddleja can significantly reduce the indicators such as AST and ALT in serum, LN, HA, PC-III, IV-C and the like in liver; in addition, the polysaccharide BOM0.05S2 can significantly reduce the deposition of collagen fibers in the liver and the expression of α-SMA protein in liver tissue; and significantly enrich Akkermansia muciniphila in the intestine, thereby playing an anti-liver fibrosis role, and therefore, it is expected to be developed as a drug for preventing / treating liver fibrosis, liver damage or other diseases related to intestinal Akkermansia muciniphila. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 This is the chromatogram of the high performance gel permeation chromatography of Buddleja buddleja polysaccharide BOM0.05S2 in (1) of Example 2.
[0050] Figure 2 The polysaccharide BOM0.05S2 of Buddleja buddleja polysaccharide (3) in Example 2 1 H NMR (A) and 13 C NMR (B) spectrum.
[0051] Figure 3 H is the H of Buddleja buddleja polysaccharide BOM0.05S2 in (3) of Example 2 1 -H 1 COSY(A), 1 HSQC and HMBC (B) spectra.
[0052] Figure 4The effect of Buddleja polysaccharide BOM0.05S2 on mouse liver injury in Example 3. (A) Schematic diagram of animal experiment; (B) The result of the kit detecting aspartate aminotransferase (AST) in mouse serum; (C) The result of the kit detecting alanine aminotransferase (ALT) in mouse serum; (D) The result of ELISA detecting type III procollagen (PC-III) in mouse liver tissue; (E) The result of ELISA detecting type IV collagen (IV-C) in mouse liver tissue; (F) The result of ELISA detecting laminin (LN) in mouse liver tissue; (G) The result of ELISA detecting hyaluronic acid (HA) in mouse liver tissue; (H) The morphological observation results of mouse liver; (I) Hematoxylin & Eosin staining (H&E) of mouse liver tissue.
[0053] Figure 5 The effect of Buddleja buddleja polysaccharide BOM0.05S2 on liver fibrosis in Example 3. (A) Sirius red staining (Sirus-Red) of liver tissue; (B) Masson staining (Masson) of liver tissue; (C) α-SMA immunohistochemical staining (IHC) of liver tissue; (A1) Quantitative analysis results of Sirius red staining using Image J; (B1) Quantitative analysis results of Masson staining using Image J; (C1) Quantitative analysis results of IHC staining using Image J; (D) Western blotting analysis of α-SMA protein expression in the liver; (E) Quantitative analysis of Western blotting results of liver tissue using Image J.
[0054] Figure 6 This is the regulation of intestinal flora by Buddleja buddleja polysaccharide BOM0.05S2 in Example 4. DETAILED DESCRIPTION
[0055] The present invention is specifically described below by way of examples. In the present invention, the following examples are intended to better illustrate the present invention and are not intended to limit the scope of the present invention. Various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.
[0056] Unless otherwise specified, the raw materials and equipment used in the specific embodiments of the present invention are conventional raw materials and reagents in the art and are purchased from the market.
[0057] Example 1 Extraction, separation and purification of Buddleja buddleja polysaccharide BOM0.05S2
[0058] (1) Extraction and separation of polysaccharides
[0059] 3kg of Buddleja buddha (origin in Sichuan) was soaked in 95% ethanol for 7 days, air-dried, added to 40L water, extracted by boiling water extraction method, 4 hours each time, and the sugar content of the extract was detected by sulfuric acid-phenol method until the sugar reaction was not obvious, and extracted 8 times in total. The extracts were combined, concentrated to a volume of 1L, and then centrifuged to remove the precipitate. The supernatant was dialyzed with convection water for two days. The dialyzed liquid was added with 95% ethanol by volume for alcohol precipitation, and stirred while adding ethanol. The volume ratio of the extract to the added ethanol was 1:4 (v / v), and it was allowed to stand overnight. The excess ethanol on the upper layer was discarded, and the precipitate was washed alternately with ethanol and acetone three times after centrifugation. The precipitate was redissolved in water, and freeze-dried to obtain 111.75g of crude polysaccharide BOM extracted from Buddleja buddha water (compared with the weight of dry medicinal materials, the yield was 3.75%).
[0060] (2) Purification of polysaccharides
[0061] Each time, 50 g of crude polysaccharide BOM extracted from Buddleja buddha flower water was dissolved in 500 mL of deionized water, stirred overnight, centrifuged, and the supernatant was loaded on DEAE Sepharose. TM Fast Flow anion exchange column, eluted with 20L deionized water and 20L 0.05M NaCl aqueous solution in turn, discarded the deionized water elution component, collected the 0.05M NaCl component, controlled the flow rate at 100mL / min, and collected in a 500mL conical flask. Take 100μL from each bottle and develop the color with sulfuric acid-phenol method and detect its absorbance at 490nm with an enzyme marker, and draw an elution curve with absorbance and elution volume. Collect the separated polysaccharides according to the elution curve, concentrate under reduced pressure, dialyze, and freeze-dry, and finally obtain the elution component of 0.05M NaCl eluate, that is, secondary crude polysaccharide BOM0.05 (7.31g).
[0062] Each time, 200 mg of secondary crude polysaccharide BOM0.05 was dissolved in 4 mL of deionized water, centrifuged (4,000 r / min), and the supernatant was loaded on a Sephacryl S-200HR gel column, eluted with 0.2 M NaCl eluent, the flow rate was controlled at 5 mL / 15 min, and collected by an automatic collector. After color development with sulfuric acid phenol method, absorbance detection with an enzyme marker and elution curve plotted, the desired separation components were collected for concentration and dialysis, and finally freeze-dried to obtain uniform buddleja polysaccharide BOM0.05S2 (1839.26 mg).
[0063] Example 2 Structural Identification of Polysaccharides
[0064] The Buddleja buddleja polysaccharide BOM0.05S2 obtained according to the method of Example 1 was identified, and the specific analysis method and results are as follows.
[0065] (1) Polysaccharide homogeneity and molecular weight determination
[0066] The average molecular weight of the polysaccharide sample BOM0.05S2 from Buddleja buddleja was determined by high performance gel permeation chromatography (HPGPC). 4 Da) and KS-804 (exclusion limit 4×10 5 Da) was analyzed on an analytical gel column, and the chromatographic conditions were as follows: mobile phase: 0.1M NaNO3; flow rate: 0.5mL / min; column temperature: 40°C; Agilent 1260 liquid chromatograph; detector: differential detector and ultraviolet detector (detection wavelength: 280nm). The characteristic spectrum obtained is as follows Figure 1 As shown, the average relative molecular mass of the Buddleja buddleja polysaccharide component sample BOM0.05S2 was determined to be 13.6 kDa.
[0067] (2) Determination of monosaccharide composition by PMP-HPLC derivatization
[0068] Preparation of monosaccharide standard solution: The monosaccharide standards are D-mannose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-glucose, D-galactose, L-xylose, L-arabinose and L-fucose. Take 9 mg of each of the above nine monosaccharides, add 1 mL of deionized water to dissolve into a 9 mg / mL solution, take 100 μL of the above solution and mix well to obtain a standard solution with a concentration of 1 mg / mL for each monosaccharide.
[0069] Preparation of monosaccharide standards: Take 50 μL of the above standard solution, add 50 μL of 0.6 M sodium hydroxide and 100 μL of 0.5 M PMP (1-phenyl-3-methyl-5-pyrazolone) methanol solution (87.1 mg / mL), derivatize in a 70°C water bath for 100 min, add 100 μL of 0.3 M hydrochloric acid solution to neutralize and terminate the reaction, then add 700 μL of deionized water and 1 mL of chloroform, vortex and extract, centrifuge and let stand at room temperature for 90 min, then draw 800 μL of the upper aqueous phase solution into a new 2 mL EP tube, discard the chloroform layer; add chloroform again, extract twice, centrifuge and take the upper aqueous phase, pass through a 0.22 μm microporous filter membrane and put into a liquid phase vial to obtain the monosaccharide standard.
[0070] Sample preparation: Take 2-3 mg of dried Buddleja buddleja polysaccharide BOM0.05S2 sample into a clean pear-shaped flask, add 2 mL of deionized water and 2 ml of 4 M trifluoroacetic acid (TFA), seal with a stopper, and completely acid hydrolyze at 110°C for 4 hours, cool to room temperature, add methanol (repeatedly) and evaporate to remove excess TFA until there is no sour taste, redissolve in 200 μL of deionized water, take 50 μL of it, add it to a new 2 mL EP tube, and the subsequent derivatization and extraction operations are the same as the preparation steps of monosaccharide standards.
[0071] Preparation of mobile phase: Weigh 13.6 g potassium dihydrogen phosphate and 1.8 g sodium hydroxide, fully dissolve in 2 L milli Q water, filter through aqueous phase membrane to obtain solution ①; mix acetonitrile (HPLC grade) and solution ① in a ratio of 17:83 (v / v), and ultrasonicate for 30 min to obtain the result.
[0072] The flow rate was set to 1 ml / min, the column temperature to 25°C, the UV detection wavelength to 254 nm, and the sample injection volume to 10 μL / sample.
[0073] The results showed that the monosaccharide composition of Buddleja buddleja polysaccharide BOM0.05S2 mainly included galactose, arabinose and a small amount of glucose, mannose, rhamnose, galacturonic acid and glucuronic acid, with the molar ratios of 47.94%, 29.12%, 7.85%, 7.64%, 3.61%, 2.20% and 1.64% respectively.
[0074] (3) Nuclear magnetic resonance analysis
[0075] Take 30 mg of Buddleja polysaccharide BOM0.05S2 sample, add 0.5 mL of D20 to dissolve, add 1.5 μL of acetone as internal standard (δ H =2.29ppm, δ C =31.5ppm), and the one-dimensional 1 HNMR, 13 C NMR, H 1 -H 1 COSY, HSQC and HMBC, the results are as follows Figure 2 , Figure 3 shown. Figure 2 A in the formula represents polysaccharide 1 H NMR spectrum, Figure 2 B stands for polysaccharide 13 C NMR spectrum, Figure 3 A represents the H of polysaccharide 1 -H 1 COSY spectrum, Figure 3 B represents the HSQC and HMBC spectra of the polysaccharide. The H1 / C1 signals of each glycoside are summarized in Table 1.
[0076] Table 1. H1 / C1 chemical shift signal assignments of BOM0.05S2 (ppm)
[0077]
[0078]
[0079] Combined with HSQC spectrum ( Figure 3B) and 13 C NMR spectrum ( Figure 2 In B), the anomeric hydrogen signals of BOM0.05S2 were assigned. 1 H-NMR( Figure 2 As shown in Figure A), the signals at δ5.15 and δ5.21 are H-1 of 1,5-α-Araf and 1,3,5-α-Araf, and their anomeric hydrogens are coupled to C-1 at δ110.51 and δ108.64, respectively. δ5.30 and δ5.17 are H-1 signals of T-α-Araf, 6110.51 is C-1 signal, and δ108.64 is carbon signal; the chemical shifts of 64.59, δ4.55, δ4.70 and δ4.75 are coupled to δ104.37, δ104.64, δ104.79 and δ105.49, respectively, corresponding to H-1 of 1,6-β-Galp, 1,3,6-β-Galp, 1,4-β-Galp and T-β-Galp. The signals at δ5.24 and δ5.15 are the anomeric hydrogen signals of 1,2,4-α-Rhap and 1,4-α-GalpA, respectively, which are coupled with the anomeric carbon signal peaks at chemical shifts of δ101.72 and δ102.00. The signal peaks at δ5.46, 65.41, 65.08 and δ5.07 are assigned to H-1 of 1,4-α-Glcp, 1,4,6-α-Glcp, T-α-Glcp and 1,4-α-GlcpA, respectively, and have coupling correlation with the signals at δ100.81, δ101.22, δ100.15 and δ99.64. The H-1 of 1,4-β-Manp and T-β-Manp are coupled with the signals at δ101.39 and 6101.39 at δ4.81 and δ4.83, respectively.
[0080] In the HMBC spectrum of BOM0.05S2 ( Figure 3In B), the correlation signals H1I4 (δ5.24, 82.59) and I4H1 (δ4.19, 101.72) indicate that H-1 of 1,2,4-α-Rhap is correlated with C-4 of 1,4-α-GalpA, and H-4 of 1,4-α-GalpA is correlated with C-1 of 1,2,4-α-Rhap. The correlation signals I1H2 (65.15, 78.63) and H2I1 (δ4.21, 102.00) indicate that H-1 of 1,4-α-GalpA is remotely associated with C-2 of 1,2,4-α-Rhap, and H-2 of 1,2,4-α-Rhap is remotely associated with C-1 of 1,4-α-GalpA. The above two groups of signals indicate that 1,4-α-GalpA and 1,2,4-α-Rhap have alternating connections. In addition, the correlation signals of G1H2 (δ4.75, 78.63) and H2G1 (δ4.21, 105.29) indicated that H-1 of T-β-Galp was linked to C-2 of 1,2,4-α-Rhap, and H-2 of 1,2,4-α-Rhap was linked to C-1 of T-β-Galp, indicating that the terminally linked Galp was linked to the C-2 site of 1,2,4-α-Rhap. The correlation signals H1M4 (65.24, 77.67) and M4H1 (δ3.72, 101.72) indicated that the H-1 site of 1,2,4-α-Rhap was remotely associated with the C-4 site of 1,4-α-GlcpA, and the H-4 site of 1,2,4-α-GlcpA was remotely associated with the C-1 site of 1,2,4-α-Rhap, indicating that the C-1 site of 1,2,4-α-GlcpA was remotely associated with the 4 sites of 1,4-α-GlcpA.
[0081] The related signals N1J4 (δ4.81, 77.84) and J4N1 (δ3.73, 101.39) indicated that the H-1 of 1,4-β-Manp was remotely associated with the C-4 of 1,4-α-Glcp, and the H-4 of 1,4-α-Glcp was remotely associated with the C-1 of 1,4-β-Manp. The related signals K1N4 (δ5.41, 77.40) and N4K1 (δ3.72, 101.22) indicated that the H-1 of 1,4,6-α-Glcp was remotely associated with the C-4 of 1,4-β-Manp, and the H-4 of 1,4-β-Manp was remotely associated with the C-1 of 1,4,6-α-Glcp. The correlation signals N1K4 (δ4.81, 77.75) and K4N1 (δ3.71, 101.39) indicated that H-1 of 1,4-β-Manp had a long-range association with C-4 of 1,4,6-α-Glcp, and H-4 of 1,4,6-α-Glcp had a long-range association with C-1 of 1,4-β-.
[0082] The correlation signals of F1F4 (δ4.70, 78.63) and F4F1 (δ4.19, 104.79) showed that H-1 of 1,4-β-Galp had long-range correlation with C-4 of 1,4-β-Galp and H-4 had long-range correlation with C-1 of 1,4-β-Galp, indicating the existence of continuously connected 1,4-β-Galp. The correlation signals of A1F4 (δ5.30, 78.63) and F4A1 (δ4.19, 110.51) showed that H-1 of T-α-Araf had long-range correlation with C-4 signal of 1,4-β-Galp, while H-4 signal of 1,4-β-Galp had long-range correlation with C-1 signal of T-α-Araf, indicating that T-α-Araf had long-range correlation with C-4 signal of 1,4-β-Galp. The correlation signals of F1H4 (δ4.70, 77.84) and H4F1 (δ3.84, 104.79) showed that there was a long-range correlation between H-1 of 1,4-β-Galp and C-4 of 1,2,4-α-Rhap and between H-4 of 1,2,4-α-Rhap and C-1 of 1,4-β-Galp, indicating that 1,4-linked Galp was attached to C-4 of 1,4-α-Rhap.
[0083] The correlation signals of B1C5 (δ5.15, 67.13) and C5B1 (δ3.86, 108.66) indicate that H-1 of 1,5-α-Araf is correlated with C-5 of 1,3,5-α-Araf, and H-5 of 1,3,5-α-Araf is correlated with C-1 of 1,5-α-Araf. The correlation signals of B1C3 (65.15, 85.06) and C3B1 (δ4.01, 108.66) indicate that H-1 of 1,5-α-Araf is correlated with C-3 of 1,3,5-α-Araf, and H-3 of 1,3,5-α-Araf is correlated with C-1 of 1,5-α-Araf. The correlation signals C1C5 (δ5.21, 67.13) and C1C1 (δ3.86, 108.74) indicate that H-5 of 1,3,5-α-Araf is remotely correlated with C-5 of 1,3,5-α-Araf, and H-5 of 1,3,5-α-Araf is remotely correlated with C-1 of 1,3,5-α-Araf. The correlation signals C1C3 (65.21, 85.06) and C3C1 (δ4.01, 108.74) indicate that H-1 of 1,3,5-α-Araf is remotely correlated with C-3 of 1,3,5-α-Araf, and H-3 of 1,3,5-α-Araf is remotely correlated with C-1 of 1,3,5-α-Araf. The correlation signals A1B5 (δ5.17, 67.41) and B5A1 (δ3.83, 108.64) showed that H-1 of T-α-Araf was correlated with C-5 of 1,5-α-Araf, and H-5 of 1,5-α-Araf was correlated with C-1 of T-α-Araf. The correlation signals A1C5 (δ5.17, 67.13) and C5A1 (δ3.86, 108.64) showed that H-1 of T-α-Araf was correlated with C-5 of 1,3,5-α-Araf, and H-5 of 1,3,5-α-Araf was correlated with C-1 of T-α-Araf. The related signals A1C3 (65.30, 85.06) and C3A1 (δ4.01, 110.51) indicate that H-1 of T-α-Araf is related to C-5 of 1,3,5-α-Araf. The related signals A1C3 (δ5.30, 85.06) and C3A1 (δ4.01, 110.51) indicate that H-1 of T-α-Araf is related to C-3 of T-α-Araf, and H-3 of 1,3,5-α-Araf is related to C-1 of T-α-Araf. The above signals indicate that arabinose is continuously and alternately connected.The correlation signals B1H4 (δ5.15, 77.84) and H4B1 (δ3.84, 108.66) indicated that the H-1 position of 1,5-α-Araf was remotely associated with the C-4 position of 1,2,4-α-Rhap, and the H-4 position of 1,2,4-α-Rhap was remotely associated with the C-1 position of 1,5-α-Araf, indicating that 1,5-α-Araf was connected to the C-4 position of 1,2,4-α-Rhap.
[0084] The correlation signals D1E6 (δ4.59, 70.71) and E6D1 (δ4.02, 104.37) indicated that the H-1 of 1,6-β-Galp was remotely associated with the C-6 of 1,3,6-β-Galp and the H-6 of 1,3,6-β-Galp was remotely associated with the C-1 of 1,6-β-Galp. The correlation signals E1D6 (δ4.55, 70.46) and D6E1 (δ3.99, 104.6) indicated that the H-1 of 1,3,6-β-Galp was remotely associated with the C-6 of 1,6-β-Galp and the H-6 of 1,3,6-β-Galp was remotely associated with the C-1 of 1,3,6-β-Galp, indicating that 1,3,6-β-Galp was alternately connected with 1,6-β-Galp. The correlation signals D1D6 (64.59, 70.46) and D6D1 (δ3.99, 104.37) indicated that H-1 of 1,6-β-Galp was remotely connected to 1,6-β-Galp on C6, and H-6 of 1,6-p-Galp was remotely connected to 1,6-β-Galp on C1, indicating that part of 1,6-β-Galp was alternately connected. The correlation signals of A1E3 (δ5.30, 81.63) and E3A1 (δ3.95, 110.51) indicated that H-1 of T-α-Araf was remotely related to C-3 of 1,3,6-β-Galp, and H-3 of 1,3,6-β-Galp was remotely associated with C-1 of T-α-Araf. The correlation signals of O1E3 (δ4.83, 81.63) and E3O1 (63.95, 101.39) indicated that H-1 of T-β-Manp was remotely associated with C-3 of 1,3,6-β-Galp and H-3 of 1,3,6-β-Galp was remotely associated with C-1 of T-β-Manp. The above two groups of signals indicated that C-3 of 1,3,6-β-Galp was connected with T-α-Araf and T-β-Manp. The correlation signals O1D6 (δ4.83, 70.46) and D6O1 (δ3.99, 101.39) indicated that H-1 of T-β-Manp was remotely associated with C-6 of 1,6-β-Galp and H-6 of 1,6-β-Galp was remotely associated with C-1 of T-β-Manp. The correlation signals E1H4 (δ4.55 / 77.84) and H4E1 (δ3.84, 104.60) indicated that H-1 of 1,3,6-β-Galp was remotely correlated with C-4 of 1,2,4-α-Rhap, and H-4 of 1,2,4-α-Rhap was remotely correlated with C-1 of 1,3,6-β-Galp, indicating that 1,3,6-β-Galp was remotely correlated with C-4 of 1,2,4-α-Rhap.
[0085] Based on this analysis, the structure of Buddleja polysaccharide BOM0.05S2 includes 1 main chain and 4 side chains, among which:
[0086] The main chain is mainly composed of 1,4-α-GalA, 1,2,4-α-Rha, 1,4-α-GlcA, 1,4-α-Glc, 1,4,6-α-Glc, 1,4-β-Man and terminal-β-Gal;
[0087] The four branches and their connection with the main chain are as follows:
[0088] Branch 1: composed of 1,4-β-Gal and T-α-Ara, and connected to C-4 of the main chain 1,2,4-α-Rha by 1,4-β-Gal;
[0089] Branch 2: It is composed of Tv-Ara, 1,5-α-Ara and 1,3,5-α-Ara, and 1,5-α-Ara is connected to C-4 of the main chain 1,2,4-α-Rha;
[0090] Branch 3: composed of 1,3,6-β-Gal and 1,6-β-Gal connected alternately, T-α-Ara and T-β-Man further connected to C-3 of 1,3,6-β-Gal in branch 3, and branch 3 connected to C-4 of main chain 1,2,4-α-Rha by 1,3,6-β-Gal;
[0091] Branch 4: consists of T-α-Glc, attached to C-6 of the main chain 1,4,6-α-Glc.
[0092] Example 3 Anti-liver fibrosis activity of Buddleja buddleja polysaccharide BOM0.05S2
[0093] The anti-fibrotic activity of Buddleja buddleja polysaccharide BOM0.05S2 in vivo was detected in mice with chronic liver fibrosis induced by carbon tetrachloride.
[0094] C57BL / 6J mice were purchased from Shanghai Slake Laboratory Animal Center and were kept in an SPF (Specific pathogen free) animal room. All experimental animals followed the Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethics Committee of the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.
[0095] C57BL / 6J male mice, weighing 22±1g, aged 6-8 weeks, were placed in a SPF animal room with a constant temperature of 22-24℃ and a humidity of 60%±5%, and were raised in a 12h light / 12h dark cycle. The mice were adapted for one week before the experiment. In the BOM0.05S2 gavage experiment ( Figure 4In Figure A), mice were randomly divided into 6 groups: negative control group (I); CCl4-induced model group (II); CCl4-induced model BOM0.05S2 low-dose administration group (III), the dose was 6.25 mg / kg; CCl4-induced model BOM0.05S2 medium-dose administration group (IV), the dose was 25 mg / kg; CCl4-induced model BOM0.05S2 high-dose administration group (V), the dose was 100 mg / kg; CCl4-induced model obeticholic acid (OCA) positive control group (VI), the dose was 30 mg / kg. There were 8 mice in each group. Mice in groups II, III, IV, V, and VI were intraperitoneally injected with 10% CCl4 (CCl4 dissolved in olive oil, the volume ratio of CCl4 to olive oil was 1:9, the dose was 2 mL / kg, 3 times a week, intraperitoneally injected for 8 consecutive weeks) to induce chronic liver fibrosis, and mice in group I were intraperitoneally injected with the same volume of olive oil. After 2 weeks of CCl4 induction, mice in groups III, IV, and V were gavaged with BOM0.05S2 (dissolved in saline) every day, mice in group VI were gavaged with obeticholic acid (dissolved in a suspension prepared with 0.5% CMC-Na) every day, and mice in groups I and II were gavaged with an equal amount of saline every day, with a dosing volume of 10 mL / kg. The dosing cycle was 6 weeks (see the experimental flow chart). Figure 4 Middle A), mice were sacrificed at the end of the experiment, and fasted for 12 hours before sacrifice. Blood and liver were collected, and the liver tissue was photographed to observe the external lesions. After the blood was allowed to stand at room temperature for 30 minutes, it was centrifuged at 2000 rpm for 30 minutes at 4°C, and the upper serum was collected and stored at -80°C. Part of the liver tissue was fixed with 4% paraformaldehyde, and part was quickly frozen in liquid nitrogen and stored at -80°C.
[0096] When the liver is damaged, the serum transaminase level will increase. Therefore, the levels of serum liver damage indicators alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected using a kit (Nanjing Jiancheng). The results showed that the levels of ALT and AST in the model group increased significantly, indicating that the liver function of mice was damaged. However, oral administration of three doses of BOM0.05S2 can reduce serum AST and ALT levels to varying degrees. The high-dose group significantly reduced serum AST and ALT levels ( Figure 4 B and C). In summary, oral administration of three doses of BOM0.05S2 improved liver damage in CCl4-induced chronic liver fibrosis model mice.
[0097] Furthermore, four indicators that can reflect liver fibrosis were also detected, including type III procollagen (PC-III), type IV collagen (IV-C), laminin (LN), and hyaluronidase (HA). The results showed that compared with the model mice induced by carbon tetrachloride, BOM0.05S2 can significantly reduce the related indicators of liver fibrosis, and it shows a concentration-dependent manner ( Figure 4 (in DG).
[0098] In order to evaluate the effect of BOM0.05S2 on the alleviation of liver damage, pictures of the liver appearance of mice were collected and the liver tissue was stained with hematoxylin-eosin (H&E) to evaluate the pathological damage of the liver of mice. The liver appearance of mice in the normal group was smooth and shiny, while the liver of mice in the model group had a gritty feel. BOM0.05S2 improved the appearance of liver lesions after intraperitoneal injection and oral administration. As the concentration of the drug increased, the liver surface gradually became smooth ( Figure 4 H in the middle). H&E results showed that the hepatocytes in the negative control group were closely arranged, and no obvious hepatocyte lesions were observed. In the model group, the hepatocytes were disorderly arranged, the number of vacuoles increased, the infiltration of inflammatory cells increased, the hepatocyte structure was destroyed, and necrosis occurred. The positive control group also had liver damage, but it was significantly less than that of the model group. High-dose BOM0.05S2 was administered orally to improve these liver pathological phenomena ( Figure 4 Middle I).
[0099] In order to evaluate the effect of BOM0.05S2 on the alleviation of fibrosis in mice with liver fibrosis, Sirius red and Masson staining were performed on liver tissue to evaluate collagen deposition; Immunohistochemistry (IHC) staining for α-SMA was performed on liver tissue to evaluate the activation of hepatic stellate cells; 40 mg of liver tissue was extracted with an animal whole protein extraction kit (Shanghai Shenggong Biological) and the protein was denatured by boiling at 100°C for 10 minutes after adding 5× loading buffer, and the protein expression of α-SMA was detected by Western blotting. The Sirius red staining results are shown in Figure 2. Figure 5 As shown in A and A1, under the optical microscope, collagen fibers are red and the background is yellow; there is no collagen deposition in the negative control group mice; the model group mice have severe collagen deposition in the vascular area and portal area; the results of Masson staining are shown in Figure 5 As shown in B and B1, the collagen fibers appeared blue under the optical microscope; there was no collagen deposition in the negative control group mice; the model group mice had severe collagen deposition in the vascular area and portal area. Figure 5As shown in C and C1, the positive signal of α-SMA is brown-yellow, indicating that the expression of α-SMA in the model group is increased, and the expression of α-SMA in the liver tissue of mice is significantly reduced after administration of BOM0.05S2. The Western blotting results of liver tissue showed that BOM0.05S2 reduced the protein expression of α-SMA after two administration methods ( Figure 5 D and E). In summary, BOM0.05S2 can significantly alleviate the degree of fibrosis in mice with liver fibrosis.
[0100] The above results indicate that oral administration of BOM0.05S2 can alleviate CCl4-induced liver fibrosis in mice.
[0101] Example 4 Buddleja polysaccharide BOM0.05S2 significantly enriched Akkermansia muciniphila in the mouse intestine
[0102] In view of the important role of intestinal flora in the occurrence and development of liver fibrosis, in order to further explore whether the anti-liver fibrosis effect of BOM0.05S2 is related to the improvement of intestinal flora composition, this study used full-length 16S rRNA gene sequencing on the cecal contents of mice sacrificed at the experimental endpoint in Example 3 to explore whether the beneficial effects of BOM0.05S2 on liver fibrosis are partially dependent on the regulation of intestinal flora imbalance. The cecal contents of mice were taken and sent to Shanghai Meiji Biomedical Technology Co., Ltd. for full-length 16S rRNA gene diversity sequencing to analyze the diversity of intestinal flora composition. The brief experimental steps are as follows:
[0103] ① Total DNA extraction from mouse cecal contents: Total DNA was extracted from mouse cecal contents according to the instructions of FastPure Stool DNA Isolation Kit (MJYH, Shanghai, China), and the integrity of DNA was detected by 1% agarose gel electrophoresis. The concentration and purity of DNA were determined using NanoDrop2000.
[0104] ②PCR amplification and sequencing library construction: Using the DNA extracted in ① as a template, the full-length 16S rRNA gene was amplified by PCR using primers 27F (5'-AGRGTTYGATYMTGGCTCAG-3'SEQ ID No.: 1) and 1492R (5'-RGYTACCTTGTTACGACTT-3'SEQ ID No.: 2) with barcode. After detection by 2% agarose gel electrophoresis, PB beads (Pacifc Biosciences, CA, USA) were used for magnetic bead purification, and the purified products were detected and quantified using Synergy HTX (Biotek, USA). According to the sequencing requirements of the samples, the corresponding proportions were mixed. The library was constructed using SMRTbell prep kit 3.0, and sequencing was performed using the Pacbio Sequel IIe System.
[0105] ③ Sequencing data analysis: PacBio data were obtained as subreads, and Hifireads (minimum full pass = 3, minimum predicted accuracy = 0.99) were obtained through SMRTLink11.0 software. The data of each sample was distinguished according to the barcode sequence, and the length was filtered to retain the sequence of 1000-1800bp. Based on the default parameters, the DADA2 plug-in in the Qiime2 process was used to denoise the optimized sequence after quality control. The sequences after DADA2 denoising are usually called amplicon sequence variants (ASVs). Based on the Silva 16S rRNA gene database, the Naive bayes classifier in Qiime2 was used to perform species taxonomy analysis on ASVs.
[0106] ④Statistical analysis: All data analyses were performed on the Meiji Biocloud platform.
[0107] The analysis results are shown in Figure 6 , showing that Buddleja buddleja polysaccharide BOM0.05S2 can significantly enrich Akkermansia muciniphila in the mouse intestine.
[0108] In summary, it can be seen from the examples that oral administration of Buddleja buddleja polysaccharide BOM0.05S2 can alleviate liver fibrosis in mice. Therefore, the polysaccharide component BOM0.05S2 can become a potential carbohydrate candidate drug or health product for the treatment or prevention of liver fibrosis, and BOM0.05S2 may exert its anti-liver fibrosis function through Akkermansia muciniphila.
[0109] The above is only an embodiment of the present invention, and the common knowledge such as the known specific structure and characteristics in the scheme is not described in detail here. It should be pointed out that for those skilled in the art, several deformations and improvements can be made without departing from the structure of the present invention, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A Buddleja buddleja polysaccharide BOM0.05S2, characterized in that: Taking the total molar amount of all monosaccharides contained in the polysaccharide as 100%, the monosaccharide composition of the polysaccharide BOM0.05S2 includes 40-50% galactose, 20-40% arabinose, 1-10% glucose, 1-10% mannose, 1-10% rhamnose, 1-10% galacturonic acid and 1-10% glucuronic acid; The structure of the Buddleja polysaccharide BOM0.05S2 includes 1 main chain and 4 side chains, wherein: The main chain is composed of 1,4-α-GalA, 1,2,4-α-Rha, 1,4-α-GlcA, 1,4-α-Glc, 1,4,6-α-Glc, 1,4-β-Man and terminal-β-Gal; The four branches and their connection with the main chain are as follows: Branch 1: composed of 1,4-β-Gal and T-α-Ara, and connected to C-4 of the main chain 1,2,4-α-Rha by 1,4-β-Gal; Branch 2: It is composed of T-α-Ara, 1,5-α-Ara and 1,3,5-α-Ara, and 1,5-α-Ara is connected to C-4 of the main chain 1,2,4-α-Rha; Branch 3: composed of alternately connected 1,3,6-β-Gal and 1,6-β-Gal, T-α-Ara and T-β-Man further connect C-3 of 1,3,6-β-Gal in branch 3, and branch 3 is connected to C-4 of main chain 1,2,4-α-Rha by 1,3,6-β-Gal; Branch 4: consists of T-α-Glc, connected to C-6 of the main chain 1,4,6-α-Glc.
2. The Buddleja buddleja polysaccharide BOM0.05S2 according to claim 1, characterized in that The monosaccharide composition of the Buddleja buddleja polysaccharide BOM0.05S2 includes galactose, arabinose, glucose, mannose, rhamnose, galacturonic acid and glucuronic acid. Taking the total molar amount of all monosaccharides contained in the polysaccharide as 100%, the proportions are 47.94%, 29.12%, 7.85%, 7.64%, 3.61%, 2.20% and 1.64% respectively.
3. The Buddleja buddleja polysaccharide BOM0.05S2 according to claim 1 or 2, characterized in that The molecular weight range of the Buddleja buddleja polysaccharide BOM0.05S2 is 3-30 kDa, preferably 10-20 kDa, and more preferably 13.6 kDa.
4. The method for preparing the Buddleja buddleja polysaccharide BOM0.05S2 according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: (1) Polysaccharide extraction: extract the Buddleja buddha flower with boiling water to obtain an extract; concentrate the extract, add ethanol aqueous solution to the obtained concentrate for alcohol precipitation, let it stand, separate the precipitate, and dry it to obtain crude Buddleja buddha flower polysaccharide BOM; (2) Polysaccharide purification: (i) dissolving the crude polysaccharide BOM of Buddleja buddleja obtained in step (1) in water and centrifuging, taking the supernatant, and performing preliminary purification using an anion exchange column, eluting with water and 0.05 M NaCl aqueous solution in sequence, collecting the eluted fraction of 0.05 M NaCl aqueous solution, and obtaining the polysaccharide fraction BOM0.05 of Buddleja bud ... (ii) dissolving the Buddleja buddleja polysaccharide component BOM0.05 obtained in step (i) in water and centrifuging the solution, taking the supernatant and purifying it through a gel column to obtain the Buddleja buddleja polysaccharide BOM0.05S2.
5. The preparation method according to claim 4, characterized in that: In step (1): Before the boiling water extraction, soak the Buddleja buddleja in an ethanol aqueous solution for 3 to 10 days and then dry it; preferably, the ethanol aqueous solution has a volume fraction of 80 to 98%, such as 95% ethanol aqueous solution; and / or In the boiling water extraction, the weight of Buddleja buddleja / water volume ratio is 1:10-20, preferably 1:12-14, unit: kg / L; the number of boiling water extractions is 3-10 times, preferably 8 times, each time for 3-5 hours, preferably 4 hours; and / or Concentrating the extract to 1 / 40 to 1 / 25 of the volume before concentration, preferably 1 / 40; and / or The volume fraction of the ethanol aqueous solution is 80-98%, preferably 95%; the volume of the ethanol aqueous solution used for alcohol precipitation is 3-6 times that of the concentrated solution; and / or Before the concentrated solution is subjected to alcohol precipitation, the concentrated solution is first centrifuged, and then the supernatant of the centrifugation is dialyzed in water for 24 to 72 hours; then the dialyzed solution is added with the ethanol aqueous solution for alcohol precipitation; and / or The standing time is 6 to 24 hours; and / or The crude polysaccharide BOM from Buddleja buddleja obtained in step (1) is washed alternately with ethanol and acetone, each washing for 2 to 4 times, before the polysaccharide purification in step (2).
6. The preparation method according to claim 4, characterized in that: In step (i) of step (2): During the dissolution process, the weight ratio of crude buddleja ... The anion exchange column is selected from the following models: DEAE Sepharose TM Fast Flow, DEAE cellucose-52, preferably DEAE Sepharose TM Fast Flow; and / or Step (i) further comprises concentrating the eluted fraction of the collected 0.05M NaCl aqueous solution, dialyzing it in water, and drying it to obtain the Buddleja buddleja polysaccharide component BOM0.05; and / or In step (ii) of step (2): In the dissolution process, the ratio of crude polysaccharide BOM from Buddleja buddleja to water is 1:10-30, for example 1:20, in g / mL; and / or The gel column is selected from the following models: Sephacryl S-200HR, Sephacryl S-300HR, Sephadex G-100 and Sephadex G-150, preferably Sephacryl S-200HR; and / or The supernatant is purified by gel column using a 0.2M NaCl aqueous solution as the eluent; and / or Step (ii) also includes collecting the eluted components and drying them to obtain Buddleja buddleja polysaccharide BOM0.05S2.
7. A pharmaceutical composition comprising the Buddleja buddleja polysaccharide BOM0.05S2 described in any one of claims 1-3 or the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method described in any one of claims 4-6, and pharmaceutically acceptable excipients.
8. Use of the Buddleja buddleja polysaccharide BOM0.05S2 according to any one of claims 1 to 3, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method according to any one of claims 4 to 6, or the pharmaceutical composition according to claim 7 in the preparation of drugs, reagents, diets or nutritional supplements having one or more of the following effects: a. Improve serum aspartate aminotransferase and / or alanine aminotransferase levels; b. Decrease in laminin, hyaluronidase, type III procollagen and / or type IV collagen in the liver; c. Inhibit the deposition of collagen fibers in liver tissue; d. Enrichment of intestinal Akkermansia muciniphila; Preferably, in use a, improvement refers to lowering the level of aspartate aminotransferase and / or alanine aminotransferase caused by liver damage; further, the liver damage is caused by chronic liver fibrosis.
9. Use of the Buddleja buddleja polysaccharide BOM0.05S2 according to any one of claims 1 to 3, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method according to any one of claims 4 to 6, or the pharmaceutical composition according to claim 7 in the preparation of a drug for preventing and / or treating liver fibrosis and / or liver damage; Preferably, the liver fibrosis is associated with Akkermansia muciniphila in the intestine.
10. Use of the Buddleja buddleja polysaccharide BOM0.05S2 according to any one of claims 1 to 3, the Buddleja buddleja polysaccharide BOM0.05S2 prepared by the preparation method according to any one of claims 4 to 6, or the pharmaceutical composition according to claim 7 in the preparation of a drug for treating diseases associated with intestinal Akkermansia muciniphila; Preferably, the diseases associated with Akkermansia muciniphila include inflammatory bowel disease, obesity, diabetes, fatty liver, and liver fibrosis.
